Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
TAETEA Group, also known as Dayi Tea Group, is a prominent Chinese tea conglomerate that has pioneered the application of modern biotechnology to traditional Pu'er tea production. The company utilizes its proprietary He-Khai microbial fermentation platform to develop functional tea products and health supplements aimed at improving metabolic and digestive health. Beyond traditional tea, TAETEA invests heavily in microbial research, tea extract purification, and the study of tea's pharmacological properties through its dedicated biotech division. With a history dating back to the Menghai Tea Factory in 1940, the modern group operates a sophisticated R&D infrastructure including the Taetea Research Institute. Their business model spans from sustainable tea cultivation to high-tech manufacturing and global retail, positioning them as a leader in the tea-based health industry.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on TAETEA Group.